Diabetes mellitus and the peripheral nervous system: Manifestations and mechanisms

被引:160
作者
Zochodne, Douglas W.
机构
[1] Univ Calgary, Dept Clin Neurosci, Calgary, AB T2N 4N1, Canada
[2] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada
关键词
diabetes mellitus; diabetic neuropathy; neuropathy; peripheral neuropathy; polyneuropathy;
D O I
10.1002/mus.20785
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Diabetes targets the peripheral nervous system with several different patterns of damage and several mechanisms of disease. Diabetic polyneuropathy (DPN) is a common disorder involving a large proportion of diabetic patients, yet its pathophysiology is controversial. Mechanisms considered have included polyol flux, microangiopathy, oxidative stress, abnormal signaling from advanced glycation endproducts and growth factor deficiency. Although some clinical trials have demonstrated modest benefits in disease stabilization or pain therapy in DPN, robust therapy capable of reversing the disease is unavailable. In this review, general aspects of DPN and other diabetic neuropathies are examined, including a summary of recent therapeutic trials. A particular emphasis is placed on the evidence that the neurobiology of DPN reflects a unique yet common and disabling neurodegenerative disorder.
引用
收藏
页码:144 / 166
页数:23
相关论文
共 286 条
  • [1] The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort
    Abbott, CA
    Carrington, AL
    Ashe, H
    Bath, S
    Every, LC
    Griffiths, J
    Hann, AW
    Hussein, A
    Jackson, N
    Johnson, KE
    Ryder, CH
    Torkington, R
    Van Ross, ERE
    Whalley, AM
    Widdows, P
    Williamson, S
    Boulton, AJM
    [J]. DIABETIC MEDICINE, 2002, 19 (05) : 377 - 384
  • [2] PROTEIN-KINASE-C INHIBITORS DECREASE HYPERALGESIA AND C-FIBER HYPEREXCITABILITY IN THE STREPTOZOTOCIN-DIABETIC RAT
    AHLGREN, SC
    LEVINE, JD
    [J]. JOURNAL OF NEUROPHYSIOLOGY, 1994, 72 (02) : 684 - 692
  • [3] VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS
    AIELLO, LP
    AVERY, RL
    ARRIGG, PG
    KEYT, BA
    JAMPEL, HD
    SHAH, ST
    PASQUALE, LR
    THIEME, H
    IWAMOTO, MA
    PARK, JE
    NGUYEN, HV
    AIELLO, LM
    FERRARA, N
    KING, GL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 331 (22) : 1480 - 1487
  • [4] AIREY M, 2000, COCHRANE DB SYST REV
  • [5] [Anonymous], 1988, DIABETES, V37, P1000
  • [6] Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy - A randomized controled trial
    Apfel, SC
    Schwartz, S
    Adornato, BT
    Freeman, R
    Biton, V
    Rendell, M
    Vinik, A
    Giuliani, M
    Stevens, JC
    Barbano, R
    Dyck, PJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (17): : 2215 - 2221
  • [7] Zonisamide in the treatment of painful diabetic neuropathy: A randomized, double-blind, placebo-controlled pilot study
    Atli, A
    Dogra, S
    [J]. PAIN MEDICINE, 2005, 6 (03) : 225 - 234
  • [8] Three-year inhibition of aldose reductase on development of symptomatic neuropathy in diabetic patients
    Baba, M
    Kimura, K
    Suda, T
    Yagihashi, S
    [J]. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2006, 11 (02) : 176 - 178
  • [9] Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus - A randomized controlled trial
    Backonja, M
    Beydoun, A
    Edwards, KR
    Schwartz, SL
    Fonseca, V
    Hes, M
    LaMoreaux, L
    Garofalo, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (21): : 1831 - 1836
  • [10] Gabapentin monotherapy for the symptomatic treatment of painful neuropathy: A multicenter, double-blind, placebo-controlled trial in patients with diabetes mellitus
    Backonja, MM
    [J]. EPILEPSIA, 1999, 40 : S57 - S59